Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Population Pharmacokinetics of Pregabalin Extended-Release in Healthy Volunteers and Patients With Postherpetic Neuralgia, Fibromyalgia, and Partial-Onset Seizures.

Chew M, Ma G, Xie R, Bockbrader H, Chapel S, Marshall S.

J Clin Pharmacol. 2019 Nov;59(11):1527-1542. doi: 10.1002/jcph.1450. Epub 2019 Jun 11.

PMID:
31183879
2.

Effect of the gastrointestinal prokinetic agent erythromycin on the pharmacokinetics of pregabalin controlled-release in healthy individuals: a phase I, randomized crossover trial.

Chew ML, Plotka A, Alvey CW, Pitman VW, Alebic-Kolbah T, Scavone JM, Bockbrader HN.

Clin Drug Investig. 2015 May;35(5):299-305. doi: 10.1007/s40261-015-0281-y.

PMID:
25808394
3.

Safety, tolerability, and pharmacokinetics of pregabalin in children with refractory partial seizures: a phase 1, randomized controlled study.

Mann D, Liu J, Chew ML, Bockbrader H, Alvey CW, Zegarac E, Pellock J, Pitman VW.

Epilepsia. 2014 Dec;55(12):1934-43. doi: 10.1111/epi.12830. Epub 2014 Nov 6.

4.

Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies.

Chew ML, Alvey CW, Plotka A, Pitman VW, Alebic-Kolbah T, Scavone JM, Bockbrader HN.

Clin Drug Investig. 2014 Sep;34(9):627-37. doi: 10.1007/s40261-014-0221-2.

PMID:
25078977
5.

Pharmacokinetics of pregabalin controlled-release in healthy volunteers: effect of food in five single-dose, randomized, clinical pharmacology studies.

Chew ML, Plotka A, Alvey CW, Pitman VW, Alebic-Kolbah T, Scavone JM, Bockbrader HN.

Clin Drug Investig. 2014 Sep;34(9):617-26. doi: 10.1007/s40261-014-0211-4.

PMID:
25078976
6.

Bioequivalence assessment of a pregabalin capsule and oral solution in fasted healthy volunteers: a randomized, crossover study.

Bockbrader HN, Alvey CW, Corrigan BW, Radulovic LL.

Int J Clin Pharmacol Ther. 2013 Mar;51(3):244-8. doi: 10.5414/CP201765.

PMID:
23357837
7.

Gabapentin to pregabalin therapy transition: a pharmacokinetic simulation.

Bockbrader HN, Budhwani MN, Wesche DL.

Am J Ther. 2013 Jan;20(1):32-6. doi: 10.1097/MJT.0b013e318250f80e.

PMID:
23018586
8.

Asenapine pharmacokinetics in hepatic and renal impairment.

Peeters P, Bockbrader H, Spaans E, Dogterom P, Lasseter K, Marbury T, Gibson GL, de Greef R.

Clin Pharmacokinet. 2011 Jul;50(7):471-81. doi: 10.2165/11590490-000000000-00000.

PMID:
21651314
9.

Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine.

Bockbrader HN, Burger P, Knapp L.

Epilepsia. 2011 Feb;52(2):405-9. doi: 10.1111/j.1528-1167.2010.02763.x. Epub 2010 Nov 3.

10.

Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy.

Shoji S, Suzuki M, Tomono Y, Bockbrader HN, Matsui S.

Br J Clin Pharmacol. 2011 Jul;72(1):63-76. doi: 10.1111/j.1365-2125.2011.03932.x.

11.

Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures.

Bockbrader HN, Burger P, Knapp L, Corrigan BW.

Epilepsia. 2011 Feb;52(2):248-57. doi: 10.1111/j.1528-1167.2010.02933.x. Epub 2011 Jan 26.

12.

Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapine.

Chapel S, Hutmacher MM, Bockbrader H, de Greef R, Lalonde RL.

Clin Pharmacol Ther. 2011 Jan;89(1):75-80. doi: 10.1038/clpt.2010.220. Epub 2010 Nov 24.

PMID:
21107314
13.

A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.

Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P.

Clin Pharmacokinet. 2010 Oct;49(10):661-9. doi: 10.2165/11536200-000000000-00000. Review.

PMID:
20818832
14.

Clinical pharmacokinetics of pregabalin in healthy volunteers.

Bockbrader HN, Radulovic LL, Posvar EL, Strand JC, Alvey CW, Busch JA, Randinitis EJ, Corrigan BW, Haig GM, Boyd RA, Wesche DL.

J Clin Pharmacol. 2010 Aug;50(8):941-50. doi: 10.1177/0091270009352087. Epub 2010 Feb 10.

PMID:
20147618
15.

Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation.

Chapel S, Hutmacher MM, Haig G, Bockbrader H, de Greef R, Preskorn SH, Lalonde RL.

J Clin Pharmacol. 2009 Nov;49(11):1297-308. doi: 10.1177/0091270009344855.

PMID:
19843656
16.

Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy.

Brodie MJ, Wilson EA, Wesche DL, Alvey CW, Randinitis EJ, Posvar EL, Hounslow NJ, Bron NJ, Gibson GL, Bockbrader HN.

Epilepsia. 2005 Sep;46(9):1407-13.

17.

Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial.

Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE.

J Pain. 2005 Apr;6(4):253-60.

PMID:
15820913
18.

Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures.

Miller R, Frame B, Corrigan B, Burger P, Bockbrader H, Garofalo E, Lalonde R.

Clin Pharmacol Ther. 2003 Jun;73(6):491-505.

PMID:
12811359
19.

Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial.

Dworkin RH, Corbin AE, Young JP Jr, Sharma U, LaMoreaux L, Bockbrader H, Garofalo EA, Poole RM.

Neurology. 2003 Apr 22;60(8):1274-83.

PMID:
12707429
20.

Pharmacokinetics of pregabalin in subjects with various degrees of renal function.

Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN.

J Clin Pharmacol. 2003 Mar;43(3):277-83.

PMID:
12638396
21.

Population pharmacokinetics of gabapentin in infants and children.

Ouellet D, Bockbrader HN, Wesche DL, Shapiro DY, Garofalo E.

Epilepsy Res. 2001 Dec;47(3):229-41.

PMID:
11738930
22.

Mucosal uptake of gabapentin (neurontin) vs. pregabalin in the small intestine.

Piyapolrungroj N, Li C, Bockbrader H, Liu G, Fleisher D.

Pharm Res. 2001 Aug;18(8):1126-30.

23.

Single-dose gabapentin pharmacokinetics and safety in healthy infants and children.

Haig GM, Bockbrader HN, Wesche DL, Boellner SW, Ouellet D, Brown RR, Randinitis EJ, Posvar EL.

J Clin Pharmacol. 2001 May;41(5):507-14.

PMID:
11361047
24.

Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability.

Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN.

Epilepsy Res. 2000 Jul;40(2-3):123-7.

PMID:
10863139
25.

Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis.

Olson SC, Bockbrader H, Boyd RA, Cook J, Koup JR, Lalonde RL, Siedlik PH, Powell JR.

Clin Pharmacokinet. 2000 May;38(5):449-59.

PMID:
10843462
26.

Transport of pregabalin in rat intestine and Caco-2 monolayers.

Jezyk N, Li C, Stewart BH, Wu X, Bockbrader HN, Fleisher D.

Pharm Res. 1999 Apr;16(4):519-26.

27.

Effects of age and gender on single-dose pharmacokinetics of gabapentin.

Boyd RA, Türck D, Abel RB, Sedman AJ, Bockbrader HN.

Epilepsia. 1999 Apr;40(4):474-9.

28.

Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy.

Gidal BE, DeCerce J, Bockbrader HN, Gonzalez J, Kruger S, Pitterle ME, Rutecki P, Ramsay RE.

Epilepsy Res. 1998 Jul;31(2):91-9.

PMID:
9714500
29.

Tandem-in-time mass spectrometry as a quantitative bioanalytical tool.

Rossi DT, Hoffman KL, Janiczek-Dolphin N, Bockbrader H, Parker TD.

Anal Chem. 1997 Nov 15;69(22):4519-23.

PMID:
9375513
30.

Contrasting nutrient effects on the plasma levels of an amino acid-like antiepileptic agent from jejunal administration in dogs.

Stevenson CM, Radulovic LL, Bockbrader HN, Fleisher D.

J Pharm Sci. 1997 Aug;86(8):953-7.

PMID:
9269874
31.

Disposition of gabapentin in anuric subjects on hemodialysis.

Wong MO, Eldon MA, Keane WF, Türck D, Bockbrader HN, Underwood BA, Sedman AJ, Halstenson CE.

J Clin Pharmacol. 1995 Jun;35(6):622-6.

PMID:
7665723
32.

Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys.

Radulovic LL, Türck D, von Hodenberg A, Vollmer KO, McNally WP, DeHart PD, Hanson BJ, Bockbrader HN, Chang T.

Drug Metab Dispos. 1995 Apr;23(4):441-8.

PMID:
7600909
33.
34.

Safety and tolerability of CI-979 in patients with Alzheimer's disease.

Sramek JJ, Sedman AJ, Reece PA, Hourani J, Bockbrader H, Cutler NR.

Life Sci. 1995;57(5):503-10.

PMID:
7623616
35.

Pharmacokinetics of gabapentin in subjects with various degrees of renal function.

Blum RA, Comstock TJ, Sica DA, Schultz RW, Keller E, Reetze P, Bockbrader H, Tuerck D, Busch JA, Reece PA, et al.

Clin Pharmacol Ther. 1994 Aug;56(2):154-9.

PMID:
8062491
36.

Lack of interaction of gabapentin with carbamazepine or valproate.

Radulovic LL, Wilder BJ, Leppik IE, Bockbrader HN, Chang T, Posvar EL, Sedman AJ, Uthman BM, Erdman GR.

Epilepsia. 1994 Jan-Feb;35(1):155-61. Erratum in: Epilepsia 1994 May-Jun;35(3):707.

PMID:
8112239
37.
41.

Effect of cimetidine administration on the pharmacokinetics of pirmenol.

Stringer KA, Lebsack ME, Cetnarowski-Cropp AB, Goldfarb AL, Radulovic LL, Bockbrader HN, Chang T, Sedman AJ.

J Clin Pharmacol. 1992 Jan;32(1):91-4.

PMID:
1740542
42.

Stereoselective high-performance liquid chromatographic assay for pirmenol enantiomers in dog plasma.

Janiczek N, Bockbrader HN, Chang T, Amidon GL, Smith DE.

J Chromatogr. 1991 Nov 15;571(1-2):179-87.

43.

Quantitative whole-body autoradiographic determination of tacrine tissue distribution in rats following intravenous or oral dose.

McNally W, Roth M, Young R, Bockbrader H, Chang T.

Pharm Res. 1989 Nov;6(11):924-30.

PMID:
2594683
44.

Formation of [20R]-dihydrodigoxin from digoxin in humans.

Reuning RH, Shepard TA, Morrison BE, Bockbrader HN.

Drug Metab Dispos. 1985 Jan-Feb;13(1):51-7.

PMID:
2858377
46.

Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function.

Guay DR, Matzke GR, Bockbrader HN, Dancik J.

Clin Pharm. 1983 Mar-Apr;2(2):157-62.

PMID:
6883944
47.

Spectral analysis of the configuration and solution conformation of dihydrodigoxigenin epimers.

Bockbrader HN, Reuning RH.

J Pharm Sci. 1983 Mar;72(3):271-4.

PMID:
6302244
48.

High-performance liquid chromatographic analysis of cimetidine in serum and urine.

Guay DR, Bockbrader HN, Matzke GR.

J Chromatogr. 1982 Mar 12;228:398-403. No abstract available.

PMID:
7076769
49.

The effect of peritoneal dialysis of the pharmacokinetics of amikacin.

Matzke GR, Salem N, Bockbrader H, Blevins R.

Proc Clin Dial Transplant Forum. 1980;10:302-4. No abstract available.

PMID:
7346850
50.

Proceedings: Apparent biological half-life values determined by administration of drug by methods other than rapid intravenous injection.

Notari RE, Kavaliunas DR, Bockbrader HN.

J Pharm Pharmacol. 1974 Dec;26 Suppl:62P-63P. No abstract available.

PMID:
4156741

Supplemental Content

Loading ...
Support Center